These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8850135)

  • 1. [Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection].
    Salomon HE; Pampuro SE; Gu Z; Montaner JS; Libonatti O; Wainberg MA
    Rev Argent Microbiol; 1995; 27(4):214-29. PubMed ID: 8850135
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
    J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia).
    Pérez-Alvarez L; Cuevas MT; Villahermosa ML; Pedreira JD; Manjón N; Herrero I; López-Calvo S; Delgado E; de Parga EV; Medrano L; Thomson MM; Taboada JA; Nájera R;
    J Hum Virol; 2001; 4(1):35-8. PubMed ID: 11213931
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 12. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral dynamics in human immunodeficiency virus type 1 infection.
    Wei X; Ghosh SK; Taylor ME; Johnson VA; Emini EA; Deutsch P; Lifson JD; Bonhoeffer S; Nowak MA; Hahn BH
    Nature; 1995 Jan; 373(6510):117-22. PubMed ID: 7529365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
    Johnson VA; Petropoulos CJ; Woods CR; Hazelwood JD; Parkin NT; Hamilton CD; Fiscus SA
    J Infect Dis; 2001 Jun; 183(11):1688-93. PubMed ID: 11343221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.
    Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ
    J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reverse transcriptase fidelity and HIV-1 variation.
    Keulen W; Nijhuis M; Schuurman R; Berkhout B; Boucher C
    Science; 1997 Jan; 275(5297):229; author reply 230-1. PubMed ID: 8999550
    [No Abstract]   [Full Text] [Related]  

  • 18. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
    Sato H; Tomita Y; Ebisawa K; Hachiya A; Shibamura K; Shiino T; Yang R; Tatsumi M; Gushi K; Umeyama H; Oka S; Takebe Y; Nagai Y
    J Virol; 2001 Jun; 75(12):5604-13. PubMed ID: 11356968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.
    Zaccarelli M; Perno CF; Forbici F; Soldani F; Bonfigli S; Gori C; Trotta MP; Bellocchi MC; Liuzzi G; D'Arrigo R; De Longis P; Boumis E; Bellagamba R; Tozzi V; Narciso P; Antinori A
    Clin Infect Dis; 2004 Feb; 38(3):433-7. PubMed ID: 14727218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.